Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort

Medical Journal of Australia

Volumn 198, Issue 8, 2013, Pages 436-439

  O'Brien, Daniel P ^a   Walton, Aaron ^a   Hughes, Andrew J ^a   Friedman, N Deborah ^a   McDonald, Anthony ^a   Callan, Peter ^a   Rhadon, Richard ^a   Holten, Ian ^a   Athan, Eugene ^a  

^a BARWON HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; BURULI ULCER; COHORT ANALYSIS; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ULCERANS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT INFECTION; REGRESSION ANALYSIS; RISK FACTOR; SKIN SURGERY; SKIN TRANSPLANTATION; SPLIT THICKNESS SKIN GRAFT; SYMPTOM; TISSUE FLAP; TREATMENT FAILURE;

AUSTRALIA; BURULI ULCER; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM ULCERANS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 84877318637     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11708     Document Type: Article

References (23)

1. World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Geneva: WHO, 2010.
2. Boyd SC, Athan E, Friedman ND, et al. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust 2012; 196: 341-344.
3. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999; 354: 1013-1018.
4. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 2006; 6: 288-296.
5. O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012; 6: e1473.
6. Kibadi K, Mputu-Yamba JB, Mokassa B, et al. [Relapse after surgical treatment of Mycobacterium ulcerans infection (Buruli ulcer): study of risk factors in 84 patients in the Democratic Republic of the Congo] [French]. Med Trop (Mars) 2009; 69: 471-474.
7. Kanga JM, Kacou DE, Sangaré A, et al. [Recurrence after surgical treatment of Buruli ulcer in Cote d'Ivoire] [French]. Bull Soc Pathol Exot 2003; 96: 406-409.
8. Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 1998; 28: 81-83.
9. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 1998; 59: 1015-1022.
10. Pak J, O'Brien DP, Quek T, Athan E. Treatment costs of Mycobacterium ulcerans in the antibiotic era. Int Health 2012; 4: 123-127.
11. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
12. Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52: 94-96.
13. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010; 54: 3678-3685.
14. World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. Geneva: WHO, 2012.
15. Steffen CM, Smith M, McBride WJ. Mycobacterium ulcerans infection in North Queensland: the "Daintree ulcer". ANZ J Surg 2010; 80: 732-736.
16. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61.
17. Bretzel G, Siegmund V, Racz P, et al. Post-surgical assessment of excised tissue from patients with Buruli ulcer disease: progression of infection in macroscopically healthy tissue. Trop Med Int Health 2005; 10: 1199-1206.
18. O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep 2008; 2: 123.
19. Pszolla N, Sarkar MR, Strecker W, et al. Buruli ulcer: a systemic disease. Clin Infect Dis 2003; 37: e78-e82.
20. Gooding TM, Johnson PD, Campbell DE, et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun 2001; 69: 1704-1707.
21. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol 2009; 27: 291-305.
22. Gordon CL, Buntine JA, Hayman JA, et al. Spontaneous clearance of Mycobacterium ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis 2011; 5: e1290.
23. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.